892396-47-3

Upstream product

• 75907-74-3 2-Pyrazinemethanol,3,5,6-trimethyl 

Downstream Products

• 892495-33-9 2-[4-(3,5-dinitrobenzoyl)-1-piperazinomethyl]-3,5,6-trimethoxypyrazine 
• 892495-35-1 2-[4-(4-nitrophenylacetyl)-1-piperazinomethyl]-3,5,6-trimethylpyrazine 
• 892495-05-5 2-(4-acetylsalicyloyl-1-piperazinomethyl)-3,5,6-trimethylpyrazine 
• 892495-41-9 2-(4-chloroacetyl-1-piperazinomethyl)-3,5,6-trimethylpyrazine 
• 1160173-55-6 2-[4-[(E)-2,5-dimethoxycinnamoyl]-1-piperazinomethyl]-3,5,6-trimethylpyrazine 

Relevant academic research and scientific papers

Design, synthesis, and biological activities of novel Ligustrazine derivatives

A series of novel Ligustrazine derivatives was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities. The results showed that most Ligustrazine derivatives exhibited lower EC50 values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine. And some Ligustrazine derivatives presented better antiplatelet aggregation activities than Ligustrazine. The derivatives containing the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency. Compound 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound 7c was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed.